![]() |
![]() |
![]() |
![]() |
P07-01 | efficacy and safety of transarterial radioembolization with yttrium-90 in patients with hepatocellular carcinoma in the context of real clinical practice | Christie Perelló | ![]() |
![]() |
|||
P01-01 | The dual role of RIP3-dependent signalling in controlling steatosis and carcinogenesis in experimental non-alcoholic steatohepatitis | Marta B. Afonso | ![]() |
![]() |
|||
P06-01 | Lymphocytes count predicts the evolution of patients with hepatocellular carcinoma treated with sorafenib | Leonardo Gomes Da Fonseca | ![]() |
![]() |
|||
P02-01 | The role of Albumin-Bilirubin grade (ALBI) and Neutrophil-lymphocyte ratio(NLR) in predicting survival in patients with Hepatocellular carcinoma(HCC) | Vinay kumar Balachandrakumar | ![]() |
![]() |
|||
LBP-01 | CDK12 inhibition mediates DNA damage and suppresses adaptive responses to sorafenib treatment in hepatocellular carcinoma | Cun Wang | ![]() |
![]() |
|||
P05-01 | Expression of galectin 3 and the clinical presentation of Hepatocellular Carcinoma recurrence after liver transplantation | Norma Filgueira | ![]() |
![]() |
|||
P03-01 | Efficacy of sorafenib and lenvatinib for hepatitis etiology: a network meta-analysis of phase III trial | Andrea Casadei Gardini | ![]() |
![]() |
|||
P06-02 | HCC recurrence after DAA treatment in HCV patients. | Maria Guarino | ![]() |
![]() |
|||
P03-02 | Thermal ablation is a safe and effective treatment for intrahepatic cholangiocarcinoma in patients with cirrhosis | Alvaro Diaz-Gonzalez | ![]() |
![]() |
|||
P05-02 | Serum levels of protein induced vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) | Silvia Gaia | ![]() |
![]() |
|||
P01-02 | Liver NK cells from NLG4 KO mice inhibited progressions of hepatocellular carcinoma of C57BL/6 mice model through decrease in p53 and AKT expressions | Johnny Amer | ![]() |
![]() |
|||
P07-02 | Thyroid hormone inhibits hepatocellular carcinoma development by reverting the metabolic reprogramming of cancer cells | ANDREA PERRA | ![]() |
![]() |
|||
LBP-02 | Attenuated XPO5-mediated export of pre-miRNA confers sorafenib resistance in HCC | Zhongjie Lin | ![]() |
![]() |
|||
P04-02 | Hepatic epithelioid hemangioendothelioma: an international multicenter study | Marco Sanduzzi Zamparelli | ![]() |
![]() |
|||
P07-03 | Lack of CCL2 limits the development of HCC in a model of obesity-associated carcinogenesis | Benedetta Piombanti | ![]() |
![]() |
|||
P01-03 | pivotal role of xist in regulating immune checkpoint pd-1/pd-l1 through a shared pathway between mir-194-5p and mir-155-5p in hepatocellular carcinoma | Sara Atwa | ![]() |
![]() |
|||
P03-03 | A novel versatile murine cholangiocarcinoma model via CRISPR/Cas9-mediated sequential oncogenic mutations of liver organoids | Michael Dill | ![]() |
![]() |
|||
P05-03 | Molecular evaluation of skin proliferative lesions in patients with hepatocellular carcinoma under sorafenib treatment | Leonardo Gomes da Fonseca | ![]() |
![]() |
|||
P04-03 | Validation of modified ALBI-T score as a prognostic model to evaluate Egyptian patients with hepatocellular carcinoma | Omar Elshaarawy | ![]() |
![]() |
|||
P06-03 | Direct-acting antiviral treatment and recurrence of hepatocellular carcinoma: a single center experience | Marco Guarracino | ![]() |
![]() |
|||
LBP-03 | The long non-coding RNA SNHG16 affects prognosis in hepatocellular carcinoma by regulating p62 expression | Jian-Hong Zhong | ![]() |
![]() |
|||
P07-04 | circulating mir-4507 as a novel prognostic biomarker in hepatocellular carcinoma | Muhammad Yogi Pratama | ![]() |
![]() |
|||
P01-04 | endocan versus alphafetoprotein as a novel biomarker in hepatitis C related cirrhosis with hepatocellular carcinoma | Abdel Ghani Badran | ![]() |
![]() |
|||
P02-04 | clinical characteristics of liver cirrhosis and hepatocellular carcinoma occurring after fontan operation | Eun Ju Cho | ![]() |
![]() |
|||
P04-04 | Oncological long term benefit in case of anatomic versus parenchyma-sparing resection for hepatocarcinoma: does the extension matter? A meta-analysis of high quality propensity matched and randomized studies. | Simone Famularo | ![]() |
![]() |
|||
LBP-04 | Influence of sustained virological response in diagnostic performance of alpha-fetoprotein for hepatocellular carcinoma in patients with HCV-cirrhosis | Ana Gómez-Outomuro | ![]() |
![]() |
|||
P03-04 | Liver polyploidization during NAFLD: a Gatekeeper against Replication Stress | Romain Donne | ![]() |
![]() |
|||
P05-04 | Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: a real-life multicentre study | Massimo Iavarone | ![]() |
![]() |
|||
P06-04 | The pattern of de novo hepatocellular carcinoma evolution in patients with hepatitis C virus following direct acting antiviral therapy needs to be clarified. | Cassia Regina Guedes Leal | ![]() |
![]() |
|||
P02-05 | Patients with hepatocellular carcinoma (HCC) treated with sorafenib who develop adverse effects during the first 60 days present a characteristic immunologic profile | Josep Corominas Argente del Castillo | ![]() |
![]() |
|||
P01-05 | The effect of socio-economic deprivation and distance to travel in the survival of patients with Hepatocellular carcinoma in Liverpool region(UK) | Vinay kumar Balachandrakumar | ![]() |
![]() |
|||
LBP-05 | Influence of treatment with direct-acting antivirals in hepatocellular carcinoma development in patients with Hepatitis C Virus-related cirrhosis | Ana Gómez-Outomuro | ![]() |
![]() |
|||
P05-05 | Experience in the use of sorafenib impacts on reasons leading to discontinuation and chance of long term response | Luca Ielasi | ![]() |
![]() |
|||
P03-05 | Radioembolization with Yttrium-90 microspheres for intermediate-advanced hepatocellular carcinoma: a single centre real-life experience | Joniada Doraku | ![]() |
![]() |
|||
P04-05 | Analysis of the HSD17B13:TA allelic variant as a protective factor towards hepatocellular carcinoma in patients with and without chronic hepatitis C | Martina Fazio | ![]() |
![]() |
|||
P06-06 | Somatic mutations and clonal dynamics in healthy and cirrhotic human liver | Matthew Hoare | ![]() |
![]() |
|||
P04-06 | Galectin 3 as a risk factor for recurrence of Hepatocellular Carcinoma after liver transplantation | Norma Filgueira | ![]() |
![]() |
|||
P05-06 | The current status of ing treatment modalities for naiive hepatocellular carcinoma patients over 70 years old : Single-center experience | Kyung Sik Kim | ![]() |
![]() |
|||
P02-06 | Dissecting the landscape of (epi-)genetic alterations during sequential evolution of liver cancer. | Carolin Czauderna | ![]() |
![]() |
|||
P07-06 | yttrium -90 trans arterial radioembolisation (tare) is an effective treatment for the downstaging of patients with hepatocellular carcinoma: a monocentric experience in a tertiary center | Helene Regnault | ![]() |
![]() |
|||
P01-06 | Anticlonogenic and apoptotic effect of metformin on cholangiocarcinoma cell line | Gulden Baskol | ![]() |
![]() |
|||
P03-06 | Globally relevant models for hepatocellular carcinoma survival applicable before and after TACE | Omar Elshaarawy | ![]() |
![]() |
|||
LBP-06 | Identification of novel epigenetic targets in the fibrotic stroma associated with HCC. | Marina Barcena-Varela | ![]() |
![]() |
|||
P05-07 | fas and p53-upregulated modulator of apoptosis in hepatocellular carcinoma cellular death | Rusdina Bte Ladju | ![]() |
![]() |
|||
P04-07 | Evaluation of LI-RADS v2018 by magnetic resonance in US-detected nodules 2cm in cirrhotics | Alejandro Forner González | ![]() |
![]() |
|||
LBP-07 | Glycogen synthase 2 (GYS2) restricts tumor metastatic ability via attenuating autophagy and breaking glycogenic homeostasis in hepatocellular carcinoma | Di Wu | ![]() |
![]() |
|||
P06-07 | External beam radiotherapy (EBRT) as an effective and safe treatment in all stages of hepatocellular carcinoma (HCC) with cirrhotic liver disease: a single western institution experience. | Clémence Hollande | ![]() |
![]() |
|||
P02-07 | Safety, and tolerability abd efficacy of transarterial chemoemebolization using drug elutind microspheres loaded with antracyclines for the treatment of patients with unresectable hepatocellular carcinome : PARIS study? | Elena Gonzalez | ![]() |
![]() |
|||
P03-07 | Non-parenchymal TREM2 halts hepatocarcinogenesis through the inhibition of liver inflammation and hepatocyte proliferation | Ibone Labiano | ![]() |
![]() |
|||
P01-07 | Sorafenib-induced pancreatic atrophy and its clinical implication in patients with hepatocellular carcinoma | Francesca Benevento | ![]() |
![]() |
|||
P07-07 | What are the predictive factors for long-term survivors with advanced hepatocellular carcinoma treated with sorafenib? | Daniela Reis | ![]() |
![]() |
|||
P04-08 | Percutaneous Microwave (MW) ablation is better than Radiofrequency (RFA) to obtain complete response in cirrhotic patients with very early and early hepatocellular carcinoma | Silvia Gaia | ![]() |
![]() |
|||
P03-08 | To cure or not to cure intermediate stage hepatocellular carcinoma beyond Milan Criteria: trans-arterial chemoembolization versus surgery in a multicentric matched cohort | Simone Famularo | ![]() |
![]() |
|||
P05-08 | Clinical safety, tolerability and adverse events of special interest in a Phase Ib study of atezolizumab (atezo) bevacizumab (bev) in hepatocellular carcinoma (HCC) | Michael Lee | ![]() |
![]() |
|||
LBP-08 | The EGF-HER2/ErBb2JNK axis drives intrahepatic cholangiocarcinoma (CCA) development | Francisco Javier Cubero | ![]() |
![]() |
|||
P02-08 | Regulation of miRNA expression by Sorafenib in primary human hepatocytes and liver cancer cells | Patricia De La Cruz-Ojeda | ![]() |
![]() |
|||
P06-08 | AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma | Massimo Iavarone | ![]() |
![]() |
|||
P07-08 | Efficacy and safety of the combination of pravastatin and sorafenib as a new therapy for the treatment of advanced hepatocellular carcinoma | Ioana Riaño | ![]() |
![]() |
|||
P07-09 | miR-21/PPARalpha activation in NASH promotes progression towards hepatocellular carcinoma | Pedro Miguel Rodrigues | ![]() |
![]() |
|||
P05-09 | cRel is a novel tumour suppressor in Hepatocellular Carcinoma | Jack Leslie | ![]() |
![]() |
|||
P04-09 | A multicentric study on real-life impact of nivolumab in patients with hepatocellular carcinoma | Leonardo Gomes Da Fonseca | ![]() |
![]() |
|||
P01-09 | Treatment of BCLC-B hepatocellular carcinoma with transarterial chemoembolization with novel polyethylene glicol doxorubicin drug-eluting microspheres: a pharmacokinetic study | Elena Gonzalez | ![]() |
![]() |
|||
P02-09 | NASH as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role: case-control study | Stefania De Lorenzo | ![]() |
![]() |
|||
P06-09 | Capecitabine in advanced hepatocellular carcinoma: a multicenter experience | Filippo Pelizzaro | ![]() |
![]() |
|||
P03-09 | comparison between rates of hepatitis c-related hepatocellular carcinoma recurrence in patients who received or not direct acting antiviral treatment | Hend Shousha | ![]() |
![]() |
|||
P01-10 | beta-catenin signaling controls NKG2D ligands expression in liver tumorigenesis | Mathilde Cadoux | ![]() |
![]() |
|||
P05-10 | The development of hepatocellular carcinoma is not predicted by genetic variants in caucasian compensated HBV cirrhotics treated by Entecavir of Tenofovir for 10 years | Alessandro Loglio | ![]() |
![]() |
|||
P07-10 | Integrative analysis defines distinct prognostic subgroups of intrahepatic cholangiocarcinoma | Stephanie Roessler | ![]() |
![]() |
|||
P02-10 | Dual CCR2/CCR5 antagonism as macrophage targeted therapy in experimental hepatocellular carcinoma | Helena Degroote | ![]() |
![]() |
|||
P04-10 | Sulfatase-2 (SULF2) in the hepatocellular carcinoma microenvironment orchestrates disease progression and therapy resistance | Misti McCain | ![]() |
![]() |
|||
P03-10 | Interventional targeting of Cyclin E1 during hepatocarcinogenesis limits stem cell traits and hepatic myeloid cell homing and attenuates cancer progression | Roland Sonntag | ![]() |
![]() |
|||
P06-10 | recurrence of hepatocellular carcinoma in patients with complete response treated with direct acting antivirals in clinical practice | Christie Perelló | ![]() |
![]() |
|||
P06-11 | line1 retrotransposons - key drivers of hepatocellular carcinoma via TGF beta signalling | Bassier Zadran | ![]() |
![]() |
|||
P04-11 | Analysis of epithelial to mesenchymal transition markers expression in liver of mice fed high fat diet | Katarzyna Mi&281;kus | ![]() |
![]() |
|||
P03-11 | AXL positive myeloid cells are expanded within tumours and in the peripheral circulation in patients with hepatocellular carcinoma | Sujit Mukherjee | ![]() |
![]() |
|||
P05-11 | Impact of screening in the average survival time of cirrhotic patients with HCC | Ana Rita Lopes | ![]() |
![]() |
|||
P02-11 | Polyploidy Spectrum: A new marker of HCC tumor classification | Chantal Desdouets | ![]() |
![]() |
|||
P07-11 | Obeticholic acid decreased alpha-Feto-protein levels in HCC through Farnesoid X receptor (FXR) | Ahmed Salhab | ![]() |
![]() |
|||
P01-11 | ESM-1 as a marker of macrotrabecular-massive hepatocellular carcinoma | Julien Calderaro | ![]() |
![]() |
|||
P05-12 | Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis | Rocio Macias | ![]() |
![]() |
|||
P02-12 | protein kinase erk5 modulates liver regeneration process in mice | Giovanni Di Maira | ![]() |
![]() |
|||
P04-12 | CXCL5 induced by the synergy of transforming growth factor-beta and Axl signaling causes neutrophil extracellular trap formation in hepatocellular carcinoma | Wolfgang Mikulits | ![]() |
![]() |
|||
P06-12 | survival and prognostic factors of patients with advanced hepatocellular carcinoma and treated with sorafinib | Hend Shousha | ![]() |
![]() |
|||
P03-12 | Hepatocellular carcinoma systemic therapy: predictive factors of sorafenib benefit | Sofia Tavares | ![]() |
![]() |
|||
P07-12 | Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease. Results from a prospective screening program. | Marco Sanduzzi Zamparelli | ![]() |
![]() |
|||
P01-12 | Analysis and characterization of mitochondrial DNA mutations in The Cancer Genome Atlas hepatocellular carcinoma cohort | Coada Camelia | ![]() |
![]() |
|||
P01-13 | Time varying mHAP III is the most accurate score in predicting survival in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemo-embolization (TACE) | Claudia Campani | ![]() |
![]() |
|||
P06-13 | Predictive factors of tumor recurrence and overall survival in patients with hepatocellular carcinoma firstly treated by locoregional therapies: results of a retrospective cohort study. | Ramy Younes | ![]() |
![]() |
|||
P03-13 | CEUS pattern of hepatocellular carcinoma: prognostic implication | Eleonora Terzi | ![]() |
![]() |
|||
P05-13 | Imaging and Clinical Features of HCC nidus: A Retrospective Study | Leonardo Pisani | ![]() |
![]() |
|||
P07-13 | Sorafenib for patients with recurrent hepatocellular carcinoma after liver transplantation: intrinsic resistance or not? | Vito Sansone | ![]() |
![]() |
|||
P04-13 | The hepatocyte specific role of the NRF2/KEAP1 axis for HCC progression during chronic liver disease | Antje Mohs | ![]() |
![]() |
|||
P04-14 | Clinical validation of the role of contrast-enhanced ultrasound in the EASL guidelines for the diagnosis of hepatocellular carcinoma | LORENZO MULAZZANI | ![]() |
![]() |
|||
P06-14 | post-transplant de novo neoplasms: role of HCC in risk stratification | SHALABY SARAH | ![]() |
![]() |
|||
P01-14 | Oncostatin M induces increased invasiveness and angiogenesis in hepatic cancer cells through HIF1-alpha-related release of VEGF-A | Stefania Cannito | ![]() |
![]() |
|||
P07-14 | Sequential systemic treatment in advanced hepatocellular carcinoma prolongs median overall survival to more than three years. | Kornelius Schulze | ![]() |
![]() |
|||
P03-14 | Efficacy and safety of thermal ablation in patients with hepatocellular carcinoma (HCC) and high comorbidity (hc) | Maria Torner | ![]() |
![]() |
|||
P05-15 | Circulating neutrophils present a dysfunctional immunophenotype in patients with hepatocellular carcinoma | João Maurício | ![]() |
![]() |
|||
P03-15 | Early experience with lenvatinib for the treatment of advanced hepatocellular carcinoma in real world practice in Japan | Kaoru Tsuchiya | ![]() |
![]() |
|||
P07-15 | Dual role of C3G in hepatocarcinoma tumor growth and progression. Implication in the HGF/c-Met signaling pathway | Celia Sequera Hurtado | ![]() |
![]() |
|||
P04-15 | Changes in the circulating miRNome profiles after therapy identify miRNA predictive biomarkers for HCC recurrence | Devis Pascut | ![]() |
![]() |
|||
P01-15 | Milticentric prospective study of validation of angiogenesis polymorphisms in hepatocellular patients treated with sorafenib. Interim analysis of INNOVATE study | Andrea Casadei Gardini | ![]() |
![]() |
|||
P02-15 | hepatocellular carcinoma identification models for patients with hcv-related chronic liver disease using data mining techniques | Hend Shousha | ![]() |
![]() |
|||
P02-16 | Energymetabolism and cell motility/adhesion defect in circulating NK-cells frompatients with Hepatocellular Carcinoma | Alessandra Zecca | ![]() |
![]() |
|||
P01-16 | Cancer stem cell sub-population drives resistance to anti-angiogenic therapies in hepatocellular carcinoma | Darko Castven | ![]() |
![]() |
|||
P04-16 | Acquisition of stem cell-like features in human cholangiocarcinoma is associated with an oxidative metabolism | Mirella Pastore | ![]() |
![]() |
|||
P03-16 | Combination of ubiquitin carboxy-terminal hydrolase L1 inhibition and Sorafenib treatment in experimental hepatocellular carcinoma dampens tumor aggressiveness and reduces in vitro functional liver cancer stem cell characteristics | Astrid Vandierendonck | ![]() |
![]() |
|||
P05-17 | impact of interval between complete ablation of hepatocellular carcinoma and start of direct acting antivirals to manage chronic hepatitis C infection | Hend Shousha | ![]() |
![]() |
|||
P01-17 | genetic variation in death receptor domain 4 (DR4) gene and the susceptibility to hepatitis-c related hepatocellular carcinoma | Hend Shousha | ![]() |
![]() |
|||
P02-17 | mtdh/aeg-1/lyric promotes tumor proliferation and targeted drug resistance in hepatocellular carcinoma | Shunjie Xia | ![]() |
![]() |
|||
P03-17 | Color Doppler and contrast-enhanced ultrasonography to manage hemorragic complications occurring after percutaneous thermal ablation of hepatocellular carcinoma. | LETIZIA VERONESE | ![]() |
![]() |
|||
P04-17 | Long-term survivors in patients with hepatocellular carcinoma: an ITA.LI.CA. report | Filippo Pelizzaro | ![]() |
![]() |
14-16 February 2019 Lisbon
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|